Eclipsebio

This week in our RNA Essentials series, we’re focusing on evaluating the critical quality attribute of RNA and LNP integrity. Swipe below to learn more about the importance of integrity assessments for therapeutic success and the analytical techniques commonly used to detect degraded RNA species. #RNAtherapeutics #QualityAttributes #DrugDevelopment #CQAs #Eclipsebio

?? New Research Highlights Small Molecule Binding Using eSHAPE ?? In this recent publication by Shah et al. at Novartis, eSHAPE was used to validate where a small molecule drug bound to RNA. This study demonstrates how RNA structure mapping can provide critical insights into small molecule interactions, paving the way for new therapeutic discoveries. ?? Congratulations to Shah et al. on this outstanding work! ?? At Eclipsebio, we’re proud to support innovative research like this with tools that empower deeper insights into RNA structure and function. Check out the publication for more details: https://lnkd.in/gjw7M5eU #RNAresearch #eSHAPE #RNAtherapeutics #RNAstructure

Help Shape the Future of RNA Therapeutic Characterization! Our team is planning for an exciting 2025, and we want your input! Where are you currently facing challenges in achieving effective quality control for your RNA-based medicines? Is it: 1?? Endosomal Escape: Struggling to robustly and reproducibly measure the efficiency of RNA delivery into the cytoplasm? 2?? Breakage Hotspots: Dealing with specific regions of RNA that are more prone to hydrolysis and degradation? 3?? Sequence Fidelity: Encountering issues with incorrect bases being misincorporated during in vitro transcription? Which type of assay would most help you achieve drug development success? ?? Cast your vote in the poll below and share your insights in the comments! Your feedback is invaluable in guiding our efforts to develop solutions that best support the RNA-based medicine community. Thank you for helping us drive innovation forward!

In this week's RNA Essentials for Critical Quality Attributes, we are diving into the world of identity characterization. Read below to discover the importance of RNA and lipid identity for therapeutic efficacy, and the analytical techniques that help to characterize the identity of the drug substance and drug product. #RNAtherapeutics #QualityAttributes #DrugDevelopment #CQAs #Eclipsebio

?? Celebrating 2 Years of Excellence with Reshma at Eclipsebio! ?? Today, we’re excited to celebrate Reshma Raghava Kurup and her remarkable contributions over the past 2 years. As a dedicated Application Scientist, Reshma has played an essential role in advancing RNA innovation, helping us support cutting-edge research in powerful ways. Her knowledge, creativity, and dedication inspire our team, and we couldn’t be more grateful for everything she brings to Eclipsebio. Thank you, Reshma, for your passion and commitment to pushing the boundaries in RNA research. Here’s to many more achievements ahead! #Eclipsebio #RNAInnovation #WorkAnniversary

New Series: RNA Essentials for Critical Quality Attributes Over the coming weeks, we will be diving into the essential critical quality attributes (CQAs) for RNA-based medicines. From potency to safety, understanding these CQAs is key to successful drug development. Each post will focus on a different CQA, breaking down why it matters and the methods used to measure it. Follow along as we explore what it takes to bring safe and effective RNA-based medicines to the clinic! #RNAtherapeutics #CQAs #DrugDevelopment #QualityStandards #Eclipsebio

Assessing critical quality attributes (CQAs) like purity, stability, and potency is essential for the successful development of RNA-based medicines. However, each CQA comes with unique measurement challenges, impacting everything from process optimization to product consistency. Which CQA do you find the hardest to measure effectively? Vote in the poll below and share your insights in the comments! #RNAVaccines #QualityAttributes #Biotech #RNAtherapeutics #Eclipsebio #Biopharma

Our CEO, Peter Chu, will be attending the 2024 annual meeting for the Alliance for mRNA Medicines – AMM ASCENT. This event brings together experts in mRNA drug development to discuss the progress and challenges of mRNA therapeutics. Peter is looking forward to discussing the future of mRNA therapeutics, sharing insights, and exploring new partnerships. Connect with us to learn more about our capabilities and how our eMERGE platform supports the development of safe and potent mRNA therapies. #AMMASCENT #mRNA #DrugDevelopment #mRNAMedicines #Eclipsebio

Reflecting on last week’s RNA and AI Symposium—what an inspiring event! It’s clear that data is the true asset driving AI innovations in RNA research and therapeutics. Many companies are ready to develop breakthrough models, but data gaps remain a key challenge. We’re here to help fill those gaps, generating clean, consistent, and reproducible data for AI applications wherever it’s needed. Looking forward to supporting even more researchers and companies in their AI-driven journeys! #RNA #AI #MachineLearning #DataInnovation #Biotech #SupportScience

Your Trusted Partner in RNA Therapeutics: Discover eMERGE Through our eMERGE platform, we provide comprehensive support for developing RNA-based medicines. As a sequencing-first platform, eMERGE offers precise and detailed characterization of RNAs to evaluate quality and optimize stability, efficacy, and safety. Whether you’re advancing a new therapy or refining your existing RNA medicines, our team brings deep expertise and a strong commitment to supporting the success of your drug development programs. Explore how eMERGE can accelerate your development timelines and drive impactful results in RNA therapeutics: https://lnkd.in/gBuYh4Bk #RNAtherapeutics #eMERGE #TherapeuticDevelopment #Eclipsebio #biotech #biopharma